Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.71 (market cap $1.66B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Nuvation Bio Inc. Class A Common Stock and uniQure N.V. Ordinary Shares are close in size by market cap, and Nuvation Bio Inc. Class A Common Stock is more actively traded (7,608,075 versus 2,488,780). Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NUVB | QURE | |
|---|---|---|
Market Cap | $1.66B | $1.48B |
Volume | 7,608,075 | 2,488,780 |
Sector | Health | Health |
52-Week High | $9.54 | $70.59 |
52-Week Low | $3.41 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $1.25B | $728.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvation Bio (NUVB) trades at $4.72, down 3.67% today, with a bearish technical outlook despite strong analyst support. The biopharma company shows promising revenue growth with $170M projected for 2026 but remains unprofitable with negative margins. Recent FDA approval for IBTROZI and Fast Track designation for safusidenib provide clinical catalysts, though cash burn remains elevated with -$121M operating cash flow in 2026.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $20.50 price target (334% upside), but investors face significant execution risk as the company burns cash to commercialize new oncology therapies. The stock offers high-risk, high-reward potential dependent on successful commercialization and path to profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
